You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
艾德生物(300685.SZ):與阿斯利康達成市場推廣合作
格隆匯 12-18 15:55

格隆匯12月18日丨艾德生物(300685.SZ)公佈,近日,公司阿斯利康製藥有限公司(阿斯利康)簽署了市場推廣協議公司自主研發的EGFR基因突變檢測試劑盒(ADx-ARMS®技術)適用於腫瘤組織標本檢測EGFR基因突變檢測試劑盒(Super-ARMS®技術)適 用於腫瘤 液體活 檢標本檢測EGFR/ALK/ROS1基因突變聯合檢測試劑盒5種突變基因檢測試劑盒(熒光PCR法)“艾惠健®等產品及相關診斷方案委託阿斯利康在中國大陸區域(不含公司直銷團隊及經銷商服務的客户)推廣。

在腫瘤伴隨診斷領域,公司嚴守國家法律和行業規範,構建了完善的、基於多技術平台的基因檢測整體解決方案。為提高腫瘤治療的有效性和針對性,雙方將充分發揮並挖掘各自的核心資源優勢,藉助公司在基因檢測領域的核心競爭力,結合阿斯利康雄厚的銷售渠道進一步推進伴隨診斷在腫瘤精準醫療中的應通過整合雙方優勢資源,有助於進一步提高公司綜合競爭力,對公司未來的發展將產生積極影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account